Does BIMEKIZUMAB Cause Product dose omission issue? 163 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 163 reports of Product dose omission issue have been filed in association with BIMEKIZUMAB (Bimzelx). This represents 6.6% of all adverse event reports for BIMEKIZUMAB.
163
Reports of Product dose omission issue with BIMEKIZUMAB
6.6%
of all BIMEKIZUMAB reports
0
Deaths
40
Hospitalizations
How Dangerous Is Product dose omission issue From BIMEKIZUMAB?
Of the 163 reports, 40 (24.5%) required hospitalization.
Is Product dose omission issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BIMEKIZUMAB. However, 163 reports have been filed with the FAERS database.
What Other Side Effects Does BIMEKIZUMAB Cause?
Psoriatic arthropathy (615)
Psoriasis (400)
Drug ineffective (293)
Inappropriate schedule of product administration (238)
Injection site pain (225)
Off label use (160)
Oral candidiasis (146)
Fatigue (138)
Therapy interrupted (138)
Pneumonia (118)
What Other Drugs Cause Product dose omission issue?
DUPILUMAB (18,189)
USTEKINUMAB (9,405)
GUSELKUMAB (9,267)
LENALIDOMIDE (8,145)
MEPOLIZUMAB (5,873)
TOFACITINIB (5,646)
VOXELOTOR (5,122)
BELIMUMAB (4,671)
SECUKINUMAB (4,572)
APREMILAST (4,460)
Which BIMEKIZUMAB Alternatives Have Lower Product dose omission issue Risk?
BIMEKIZUMAB vs BIMEKIZUMAB-BKZX
BIMEKIZUMAB vs BINIMETINIB
BIMEKIZUMAB vs BIOFLAVONOIDS
BIMEKIZUMAB vs BIOTIN
BIMEKIZUMAB vs BIPERIDEN